USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A new immune-oncology company with a novel approach to chimeric antigen receptor (CAR) T-cell therapy has been launched by Puretech, it has been announced. 10 May 2016
US clinical-stage biopharma firm Sorrento Therapeutics has announced that it has engaged financial advisors to explore strategic alternatives to maximize shareholder value. 10 May 2016
Italian drugmaker Recordati has published first quarter 2016 financial results showing revenue was 9.6% higher than it was for the same period in 2015. 5 May 2016
US biotech Regeneron has raised its revenue estimates for the year due to increased first quarter 2016 sales of its Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema (DME). 5 May 2016
A growth in total revenue driven by selling or out-licensing non-core products could not prevent core operating profit for the first quarter of 2016 to decline at pharma major AstraZeneca. 29 April 2016
Shares in Dublin-based Shire pharmaceuticals rose by 4% after the company posted better-than-expected first quarter results, a day after investors revolted against chief executive pay deal. 29 April 2016
Shares in US biotech firm Celgene fell 1.5% in pre-market trading following publication of the company’s first quarter 2016 financial results. 28 April 2016
US pharma major Bristol-Myers Squibb saw its revenue increase by 9% to $4.4 billion in the first quarter of 2016 compared to the same period a year ago. 28 April 2016
Increased sales of new products, better profit margins and internal restructuring and integration have been cited as reasons for pharma major GlaxoSmithKline reporting strong first-quarter growth for 2016. 27 April 2016
UK-based commercial stage pharmaceutical company Vernalis is set to raise more than $58 million in a share issue to help pay for its roll-out of new products. 27 April 2016
Rare disease specialist Swedish Orphan Biovitrum has signed a licensing agreement with biotech company Affibody AB for the development of novel treatments for inflammatory diseases where interleukin-1 (IL-1) is involved. 22 April 2016
An exponential growth in the global digital health market is giving pharma and life science companies a clear opportunity to play a greater role in delivering improved patient experiences, better clinical outcomes and cost-savings. 18 April 2016
US biotech Regeneron Pharmaceuticals and Intellia Therapeutics have signed a licensing and collaboration agreement to advance CRISPR/Cas 9 gene editing technology. 12 April 2016
Starboard Value, a privately owned hedge fund sponsor, has written a strongly-worded letter to US specialty drugmaker Depomed, in which the investor now owns almost 10% of the shares. 11 April 2016
The pharmaceutical industry’s investment in Finland totalled 220 million euros ($250 million) in 2015, the domestic trade group has said. 11 April 2016
Privately-held Servier has marked 40 years of operations in Brazil by announcing plans to launch 15 new meds not only for diabetes, but also for cancer and cardiovascular diseases – the country’s second biggest killers. 7 April 2016
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news